Potential new class of drugs may reduce cardiovascular risk by targeting gut microbes

August 6, 2018, Cleveland Clinic
Credit: CC0 Public Domain

Cleveland Clinic researchers have designed a potential new class of drugs that may reduce cardiovascular risk by targeting a specific microbial pathway in the gut.

Unlike antibiotics, which non-specifically kill gut bacteria and can lead to adverse side effects and resistance, the new class of compounds prevents microbes from making a harmful molecule linked to heart disease without killing the microbes, which are part of the and may be beneficial to overall health.

In the study, which took place in mice, the new drugs reversed two major risk factors for cardiovascular disease—increased platelet responsiveness and excessive clot formation—by lowering levels of TMAO (trimethylamine N-oxide), a gut bacteria byproduct that forms during digestion.

The research was published in the September issue of Nature Medicine and was led by Stanley Hazen, M.D., Ph.D.

High levels of TMAO in the blood have been shown to be a powerful tool for predicting future heart attack, stroke and death risks, according to previous research initially spearheaded by Dr. Hazen and his team, and subsequently replicated around the world. TMAO testing is now in clinical use as a result.

In several landmark studies in the last five years, Dr. Hazen's team was the first to demonstrate that the metabolite TMAO is produced when gut bacteria digest choline, lechithin and carnitine, nutrients that are abundant in animal products such as red meat and liver. Choline is also abundant in egg yolk and high-fat dairy products. Dr. Hazen's group went on to show that TMAO affects platelet reactivity and thrombosis (clotting) potential, which lead to a higher risk of myocardial infarction (heart attack) and stroke.

Cleveland Clinic study finds potential new class of drugs may reduce cardiovascular risk by targeting gut microbes. Credit: Cleveland Clinic

In this new study, Dr. Hazen's group demonstrated that a new series of inhibitors, called mechanism-based inhibitors, potently interrupt the gut microbial pathway that produces TMAO. Because the compounds are structurally similar to choline (called analogues), the bacterial cells are "tricked" into taking them up as nutrients. Once transported into the microbe, the inhibitors then block the production of TMAO by inactivating a specific gut microbe enzyme called cutC (choline utilization protein C).

"To our knowledge, this is the most potent therapy to date for 'drugging' the microbiome to alter a disease process. In addition, are altered but not killed by this drug, and there were no observable toxic side effects," said Dr. Hazen. "The approach developed could potentially be used to target other gut microbial pathways. We look forward to advancing this novel therapeutic strategy into humans."

The group found that a single oral dose of one of the potent inhibitors in animal models significantly reduced TMAO levels in the blood for up to three days and reversed both enhanced platelet responsiveness and heightened thrombus (clot) formation following arterial injury. Once taken, the drugs were minimally absorbed into the body, and instead stayed in the gut where they targeted just the microbial pathway. The drugs also reduced "hyperresponsive" platelet function to normal, inhibiting excessive blood clot formation but with very little risk for increased bleeding, which is a common side effect of other anti-platelet therapies.

In addition, the drugs were designed to not kill the bacterial cells and, therefore, likely do not contribute to antibiotic resistance.

Explore further: Researchers show dietary choline and TMAO linked with increased blood clotting

More information: Adam B. Roberts et al, Development of a gut microbe–targeted nonlethal therapeutic to inhibit thrombosis potential, Nature Medicine (2018). DOI: 10.1038/s41591-018-0128-1

Related Stories

Researchers show dietary choline and TMAO linked with increased blood clotting

April 24, 2017
Cleveland Clinic researchers have shown, for the first time in humans, that choline is directly linked to increased production of a gut bacteria byproduct that increases the risk of blood-clotting events like heart attack ...

Altering gut bacteria pathways may stimulate fat tissue to prevent obesity

June 30, 2017
Cleveland Clinic researchers have uncovered a biological link between gut bacteria metabolism and obesity. The team showed that blocking a specific intestinal microbial pathway can prevent obesity and insulin resistance, ...

Study shows gut microbes influence platelet function, risk of thrombosis

March 10, 2016
Cleveland: In a combination of both clinical studies of over 4,000 patients and animal model studies, Cleveland Clinic researchers have demonstrated—for the first time—that gut microbes alter platelet function and risk ...

Researchers identify potential approach to treat heart disease through the gut

December 17, 2015
Cleveland Clinic researchers have demonstrated - for the first time—that targeting microbes in the gut may prevent heart disease brought on by nutrients contained in a diet rich in red meat, eggs and high-fat dairy products.

Gut bacteria byproduct linked to chronic kidney disease for the first time

January 29, 2015
Cleveland Clinic researchers have, for the first time, linked trimethylamine N-oxide (TMAO) - a gut metabolite formed during the digestion of egg-, red meat- or dairy-derived nutrients choline and carnitine - to chronic kidney ...

Study shows gut bacteria byproduct predicts heart attack and stroke

April 24, 2013
A microbial byproduct of intestinal bacteria contributes to heart disease and serves as an accurate screening tool for predicting future risks of heart attack, stroke and death in persons not otherwise identified by traditional ...

Recommended for you

Antibodies linked to heart attacks

October 23, 2018
Levels of antiphospholipid antibodies, which are associated with rheumatic diseases, are also elevated in myocardial infarction without any autoimmune co-morbidity, a study from Karolinska Institutet in Sweden published in ...

Targeting a hunger hormone to treat obesity

October 22, 2018
About 64 per cent of Canadian adults are overweight or obese, according to Health Canada. That's a problem, because obesity promotes the emergence of chronic diseases such as type 2 diabetes, heart disease and some cancers.

Scientists in Sweden may have figured out one way acne bacteria defies treatment

October 22, 2018
Researchers in Sweden have discovered how acne-causing bacteria feed off their human hosts. The study, which was performed at KTH Royal Institute of Technology, could make it possible to find effective ways to treat severe ...

Poor oral health linked to higher blood pressure, worse blood pressure control

October 22, 2018
People with high blood pressure taking medication for their condition are more likely to benefit from the therapy if they have good oral health, according to new research in the American Heart Association's journal Hypertension.

Gene plays critical role in noise-induced deafness

October 19, 2018
In experiments using mice, a team of UC San Francisco researchers has discovered a gene that plays an essential role in noise-induced deafness. Remarkably, by administering an experimental chemical—identified in a separate ...

Scientists grow functioning human neural networks in 3-D from stem cells

October 18, 2018
A team of Tufts University-led researchers has developed three-dimensional (3-D) human tissue culture models for the central nervous system that mimic structural and functional features of the brain and demonstrate neural ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.